2 results
Approved WMOCompleted
Primary objective To investigate the safety and tolerability of CCS1477 as monotherapy and in combination.
Approved WMORecruiting
The primary endpoint is the evaluation of the safety and toxicity of TIL with nivolumab and, thereafter, the safety and toxicity of the combination of PEG-IFNa, nivolumab plus TIL. Safety and toxicity will be evaluated according to CTCAE 4.0…